About Us

Board of Directors

Our board members have extensive experience in the pharmaceutical industry, and their guidance helps us bring important therapeutics to patients in need.

John A. Fallon, M.D.
Former Senior Vice President and Chief Physician Executive at Blue Cross & Blue Shield of Massachusetts
John Fallon, M.D. has been a director since September 2014. Dr. Fallon most recently served as senior vice president and chief physician executive at Blue Cross & Blue Shield of Massachusetts...
John Fallon, M.D. has been a director since September 2014. Dr. Fallon most recently served as senior vice president and chief physician executive at Blue Cross & Blue Shield of Massachusetts (BCBSMA) from 2004 through 2015. Prior to his role at BCBSMA, Dr. Fallon served as chief executive officer for clinical affairs at the State University of New York Downstate Medical Center, including University Hospital of Brooklyn and the clinical faculty practice plan. His professional experience also includes the Partners Healthcare System, where he was chairman of the physician network. Dr. Fallon was the founder and CEO of North Shore Health System, a large physician-hospital organization in Massachusetts. He serves on the board of directors of Insulet Corporation, Exact Sciences and Collegium Pharmaceuticals. He also serves on several not-for-profit boards, including Network for Excellence in Health Innovation (Chair), recently retired from National Committee for Quality Assurance Medical Standards (Chair) and Temple University School of Medicine Board of Advisors until November 2017. Dr. Fallon practiced internal medicine for more than 20 years, fulfilled his residency at Boston City Hospital, is Board Certified in Internal Medicine and is a fellow of the American College of Physicians. He received a Bachelor of Science degree from the College of the Holy Cross, a Master of Business Administration from the University of South Florida and a Doctor of Medicine degree from Tufts University School of Medicine.
Paul Fonteyne
Former Chairman of BI USA and President of Animal Health for Boehringer-Ingelheim USA Corporation
Paul Fonteyne has been a director since October 2019. Mr. Fonteyne is the retired chairman and CEO of Boehringer-Ingelheim (BI) USA. He was with Boehringer-Ingelheim for 15 years in leadership roles...
Paul Fonteyne has been a director since October 2019. Mr. Fonteyne is the retired chairman and CEO of Boehringer-Ingelheim (BI) USA. He was with Boehringer-Ingelheim for 15 years in leadership roles both in the U.S. and globally. During this time, he led teams that grew BI’s sales and earnings several fold in the U.S. and participated in acquisitions and divestitures that led to a significantly greater focus of BI’s portfolio of companies in the U.S. in two main segments of Animal Health and Human Pharmaceuticals. During his more than 30 years in the pharmaceutical industry, Paul also held commercial leadership roles at Merck & Co. Inc. for nine years, and Abbott Laboratories for eight years. Mr. Fonteyne serves on the Board of Directors of several clinical-stage biotechnology companies including Gelesis, DalCor (Chairman), ResTorbio inc. (Chair of compensation Committee), and Ypsomed AG, a device company. He has also served on the Board of PhRMA and chaired the National Pharmaceutical Council and served as Chair of the American Cancer Society CEOs Against Cancer. In addition, Mr. Fonteyne serves as an Executive in Residence to Canaan Partners, a Venture Capital Fund dedicated to early stage venture investing in healthcare and technology where he advises several companies in the Canaan portfolio. Mr. Fonteyne holds an M.S. in Chemical Engineering from the University of Brussels and an MBA for Carnegie Mellon University.
David Johnson
Partner and co-Founder of Caligan Partners LP
David Johnson is a Partner and co-Founder of Caligan Partners LP, an investment manager. Previously, Mr. Johnson was a Managing Director at The Carlyle Group, where he was employed from 2010 to 2017....
David Johnson is a Partner and co-Founder of Caligan Partners LP, an investment manager. Previously, Mr. Johnson was a Managing Director at The Carlyle Group, where he was employed from 2010 to 2017. At Carlyle, Mr. Johnson was involved in many of the firm's strategic initiatives and sat on investment committees for a number of different funds that invested in both equity and credit. Prior to joining Carlyle, Mr. Johnson worked for six years at Morgan Stanley, where he was a Vice President in the Principal Investments area. In this role, Mr. Johnson served as a director of SeaChange Maritime Limited, and an observer of numerous company boards. Prior to joining Morgan Stanley, Mr. Johnson worked at Weiss Asset Management in Boston, MA, during which time he served on the board of the Kazakhstan Investment Fund. Mr. Johnson has served on the Executive Committee for the Harvard College Fund, is a member of the board of directors of the Children's Scholarship Fund, and is Chair of the Finance & Investment Committee for the Riley's Way Foundation. Mr. Johnson received his A.B. in Applied Mathematics, cum laude, from Harvard College in 2004 and a S.M. in Applied Mathematics from Harvard College in 2004.
Scott Myers
President and Chief Executive Officer of AMAG Pharmaceuticals, Inc.
Scott Myers has been a director since April 2020. Mr. Myers is a proven executive who brings nearly three decades of global pharmaceutical and medical technology experience who has been President and...
Scott Myers has been a director since April 2020. Mr. Myers is a proven executive who brings nearly three decades of global pharmaceutical and medical technology experience who has been President and Chief Executive Officer of AMAG since April 2020. Mr. Myers most recently served as Chairman and Chief Executive Officer of Rainier Therapeutics, a clinical-stage biotechnology company focused on metastatic bladder cancer. Prior to joining Rainier, Mr. Myers served as Chief Executive Officer, President and Director of Cascadian Therapeutics Inc. Mr. Myers also served as Chief Executive Officer of Aerocrine AB, a medical device company from 2011 to 2015. While at the helm of these companies, Mr. Myers drove transformation that maximized growth and delivered significant long-term value. Mr. Myers is currently an Independent Director for Selecta Biosciences where he serves as the Chair of the Compensation and Benefits Committee, as well as a member of the Nominating and Governance Committee. Mr. Myers also serves as an Independent Director for Harpoon Therapeutics, a clinical stage biotechnology company where he serves on the Audit Committee. Mr. Myers began his career in management consulting and then moved into the pharmaceutical industry through senior leadership roles at Johnson & Johnson, DOV Pharmaceuticals and UCB. Mr. Myers holds a Bachelor of Arts in Biology from Northwestern University in Evanston, Illinois, and a Master of Business Administration from The University of Chicago Graduate School of Business (Booth) in Chicago, Illinois.
Kathrine O’Brien
Former Vice President and General Manager, Skin and Marketing Services for Unilever PLC
Kathrine O’Brien has been a director since April 2019. Ms. O’Brien is an experienced consumer marketing executive with a focus on women’s personal care products. She joins the board with a deep...
Kathrine O’Brien has been a director since April 2019. Ms. O’Brien is an experienced consumer marketing executive with a focus on women’s personal care products. She joins the board with a deep understanding and knowledge of consumer and digital engagement. In her most recent role at Unilever, Ms. O’Brien initiated, implemented and led direct-to-consumer digital marketing strategies for the skin care business. She is also a director on the board of Tabala Rasa Healthcare, Inc. Ms. O’Brien holds a Bachelor of Arts in economics from Boston College and a Master of Business Administration from Columbia University.
Anne M. Phillips, M.D., FRCPC,
Senior Vice President, Clinical Development, Medical and Regulatory Affairs for Novo Nordisk, Inc.
Anne Phillips, M.D. has been a director since April 2019. In her current role at Novo Nordisk, Dr. Phillips is responsible for medical and regulatory affairs and the clinical development of the Novo...
Anne Phillips, M.D. has been a director since April 2019. In her current role at Novo Nordisk, Dr. Phillips is responsible for medical and regulatory affairs and the clinical development of the Novo Nordisk portfolio of compounds, including product lifecycle initiatives.Prior to Novo Nordisk, Dr. Phillips served in various roles of increasing responsibility from 1998 to 2010 at GlaxoSmithKline plc. Dr. Phillips also served as the Head of the Infectious Diseases Program and Deputy Physician-in-Chief at Wellesley Central Hospital/St. Michael’s Hospital in Toronto, Canada. She is also a director on the board of Trevena, Inc. Dr. Phillips is a Fellow of The Royal College of Physicians and Surgeons of Canada, and earned a medical degree from the University of Toronto and received a Bachelor of Sciences from the University of Western Ontario.
Gino Santini
Chairman of the Board, AMAG; Retired Eli Lilly and Company Executive
Gino Santini has been a director since February 2012 and chairman of the board since April 2014. In 2010, Mr. Santini retired from a distinguished career with Eli Lilly and Company that spanned nearly...
Gino Santini has been a director since February 2012 and chairman of the board since April 2014. In 2010, Mr. Santini retired from a distinguished career with Eli Lilly and Company that spanned nearly three decades. During his tenure at Eli Lilly and Company, Mr. Santini held various leadership positions of increasing responsibility, including manager of various international regions, senior vice president of corporate strategy and policy, president of U.S. operations, and president of the women's health franchise. Mr. Santini capped his career at Eli Lilly and Company as a member of the company’s executive committee and as the Senior Vice President of Corporate Strategy and Business Development. Mr. Santini currently serves on the boards of directors of Intercept Pharmaceuticals Inc., where he is chair of the compensation committee and a member of the audit committee, Intarcia Therapeutics Inc., where he is chair of the transaction committee and a member of the audit committee, and Collegium Pharmaceuticals, Inc., where he is lead independent director, chair of the nominating and governance committee and member of the compensation committee. He is also a member of the board of direct of Allena Pharmaceuticals, Inc., where he is chair of the compensation committee and member of the audit committee, Horizon Pharma Plc., where he is also chair of the transactions committee and member of the compensation committee, and Artax Biopharma Inc. Mr. Santini is fluent in four languages, holds an undergraduate degree in mechanical engineering from the University of Bologna and a Master of Business Administration from the University of Rochester
Davey S. Scoon, CPA
Non-Executive Chairman, Board of Directors Tufts Health Plan
Davey Scoon has been a director since December 2006. Mr. Scoon has more than 30 years of experience in finance and administration in executive positions. From 2003 to 2005, Mr. Scoon was chief...
Davey Scoon has been a director since December 2006. Mr. Scoon has more than 30 years of experience in finance and administration in executive positions. From 2003 to 2005, Mr. Scoon was chief administrative and financial officer of Tom’s of Maine, a company that manufactures natural care products. From 2001 to 2003, Mr. Scoon served as chief financial and administrative officer for Sun Life Financial U.S. and from 1999 to 2001, Mr. Scoon served as vice president and chief financial officer for Sun Life Financial U.S. From 1985 to 1999, Mr. Scoon was employed by Liberty Funds Group of Boston (formerly Colonial Management) in various capacities including chief financial officer and chief operating officer. Mr. Scoon is the retired Board chair of Tufts Health Plan where he served as a director from 1981 to 2015. He currently serves as chairman of the board of trustees of Allianz Funds, is a member of the board of directors of Biodel Inc and serves as audit chair for Albireo, a successor company of Biodel. He has been an Adjunct Professor at the University of Wisconsin-Madison School of Business since 2010. Mr. Scoon holds a Bachelor of Business Administration from the University of Wisconsin and a Master of Business Administration from Harvard Business School, and is a Certified Public Accountant.
James Sulat
Former Chief Executive Officer and Chief Financial Officer at Maxygen, Inc.
James Sulat has been a director since April 2014. From 2009 to 2013, Mr. Sulat served as Chief Executive Officer and Chief Financial Officer of Maxygen, Inc., and as a member of Maxygen's Board of...
James Sulat has been a director since April 2014. From 2009 to 2013, Mr. Sulat served as Chief Executive Officer and Chief Financial Officer of Maxygen, Inc., and as a member of Maxygen's Board of Directors from 2003 to 2013. From 2005 to 2009, Mr. Sulat served in several roles for Memory Pharmaceuticals Corp., including as President and Chief Executive Officer from 2005 to 2008 and as a member of Memory's Board of Directors from 2005 to 2009. Previously, Mr. Sulat served as Chief Financial Officer for Chiron Corporation and Stanford Health Services. Mr. Sulat serves on the boards of Arch Therapeutics, Momenta Pharmaceuticals, and Valneva SE. Mr. Sulat received a Bachelor of Science in Administrative Sciences from Yale University and a Master of Business Administration and a Master of Science in Health Services Administration from Stanford University.